Research Article

Chinese Patent Medicine as Adjuvant for Mild-to-Moderate Active Ulcerative Colitis: A Network Meta-Analysis of Randomized Controlled Trials

Table 4

Results of the pairwise meta-analysis.

ComparisonAdverse eventsRecurrence rateDisappearance of mucopurulent bloody stoolDisappearance of abdominal painDisappearance of diarrheaDisappearance of tenesmusMayo score
nRR [95% CI]nRR [95% CI]nRR [95% CI]nRR [95% CI]nRR [95% CI]nRR [95% CI]nMD [95% CI]

XLSplusM vs. M11.45 [0.26, 7.99]10.32 [0.07, 1.46]11.34 [1.00, 1.80]11.32 [1.01, 1.72]11.36 [0.98, 1.89]
XLS vs. M20.14 [0.02, 1.05]11.03 [0.74, 1.43]11.21 [0.88, 1.66]11.03 [0.72, 1.49]
HDplusPLA vs. MplusPLA11.27 [1.02, 1.59]11.31 [0.98, 1.75]
HDplusM vs. MplusPLA11.31 [1.06, 1.63]11.38 [1.05, 1.80]
KFXplusM vs. M61.19 [0.69, 2.04]60.29 [0.17, 0.51]11.23 [1.01, 1.49]11.25 [1.02, 1.54]11.27 [1.01, 1.59]11.31 [1.03, 1.68]
YNBY vs. ZK10.53 [0.04, 7.50]11.89 [1.01, 3.55]11.70 [0.94, 3.08]11.70 [0.94, 3.08]11.89 [1.01, 3.55]
BPYCplusM vs. M10.33 [0.07, 1.51]12.47 [1.65, 3.70]11.89 [1.32, 2.71]
ZKplusM vs. M11.08 [0.27, 4.41]11.36 [0.90, 2.06]11.61 [0.90, 2.88]11.53 [0.96, 2.42]10.64 [0.30, 1.36]
YNBYplusM vs. M10.50 [0.10, 2.53]11.42 [0.83, 2.44]
DSFplusM vs. M11.60 [0.56, 4.61]10.22 [0.09, 0.53]
DSIplusM vs. M21.09 [0.50, 2.37]10.55 [0.22, 1.37]1−1.60 [−2.26, −0.94]
JCNplusM vs. M1−0.22 [−1.19, 0.75]
FFHBplusM vs. M11.50 [0.57, 3.95]
FFKSplusPLA vs. MplusPLA12.38 [0.27, 21.05]
FZLZplusM vs. M11.33 [0.31, 5.70]
SMIplusM vs. M10.83 [0.27, 2.55]
CYNplusM vs. M30.99 [0.36, 2.77]
GCZXplusM vs. M10.78 [0.52, 1.17]
KFXplusM vs. YNHYplusKFXplusM10.20 [0.01, 4.00]
YNBYplusSJSplusXLSplusM vs. M10.46 [0.12, 1.71]

Significant results are in bold.